(LMAT) LeMaitre Vascular - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5255582018
LMAT: Vascular Grafts, Catheters, Patches, Shunts, Biosynthetic Grafts, Medical Tapes
LeMaitre Vascular Inc. (NASDAQ:LMAT) is a leading developer, manufacturer, and marketer of medical devices and implants tailored for vascular surgery. The companys product portfolio addresses a wide array of vascular procedures, including peripheral bypass surgeries, dialysis access, and carotid endarterectomy. Their offerings include human cadaver tissue cryopreservation services, angioscopes for visualizing blood vessel interiors, and various catheters for embolectomy, thrombectomy, and perfusion. Additionally, they provide a range of biologic grafts and patches, such as Artegraft and XenoSure, used in vessel repair and reconstruction.
LeMaitres innovative products extend to biosynthetic vascular grafts for lower extremity bypass and dialysis access, and they offer unique solutions like radiopaque tape, which aids surgeons in locating subcutaneous structures. Their valvulotomes and closure systems using titanium clips enhance surgical efficiency. The companys strategic approach is evident in its direct sales force and distributor network, ensuring comprehensive market reach. Established in 1983 and renamed in 2001, LeMaitre is headquartered in Burlington, Massachusetts.
From an investment perspective, LeMaitre Vascular presents a compelling profile with a market capitalization of $2.17 billion, reflecting a P/E ratio of 53.26 and a forward P/E of 46.08. The price-to-book ratio stands at 6.80, and the price-to-sales ratio is 10.23, indicating a premium valuation. These metrics suggest a company positioned for growth, supported by a strong product pipeline and a solid financial foundation, making it an attractive consideration for investors and fund managers focusing on the medical device sector.
Additional Sources for LMAT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LMAT Stock Overview
Market Cap in USD | 2,218m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2006-10-19 |
LMAT Stock Ratings
Growth 5y | 91.5% |
Fundamental | 34.7% |
Dividend | 62.9% |
Rel. Strength Industry | 60.6 |
Analysts | 4.1/5 |
Fair Price Momentum | 108.07 USD |
Fair Price DCF | 9.36 USD |
LMAT Dividends
Dividend Yield 12m | 0.64% |
Yield on Cost 5y | 2.21% |
Annual Growth 5y | 10.99% |
Payout Consistency | 100.0% |
LMAT Growth Ratios
Growth Correlation 3m | -40.7% |
Growth Correlation 12m | 93.8% |
Growth Correlation 5y | 84.4% |
CAGR 5y | 28.37% |
CAGR/Mean DD 5y | 2.14 |
Sharpe Ratio 12m | 1.49 |
Alpha | 40.72 |
Beta | 0.88 |
Volatility | 33.47% |
Current Volume | 180.9k |
Average Volume 20d | 160.3k |
As of February 19, 2025, the stock is trading at USD 100.74 with a total of 180,869 shares traded.
Over the past week, the price has changed by +3.92%, over one month by +1.09%, over three months by -2.56% and over the past year by +62.50%.
Neither. Based on ValueRay Fundamental Analyses, LeMaitre Vascular is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 34.65 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LMAT as of February 2025 is 108.07. This means that LMAT is currently overvalued and has a potential downside of 7.28%.
LeMaitre Vascular has received a consensus analysts rating of 4.10. Therefor, it is recommend to buy LMAT.
- Strong Buy: 4
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, LMAT LeMaitre Vascular will be worth about 129.7 in February 2026. The stock is currently trading at 100.74. This means that the stock has a potential upside of +28.73%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 98.4 | -2.3% |
Analysts Target Price | 98.8 | -1.9% |
ValueRay Target Price | 129.7 | 28.7% |